Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
43.3M
-
Shares change
-
+4.19M
-
Total reported value, excl. options
-
$1.37B
-
Value change
-
+$105M
-
Number of buys
-
74
-
Number of sells
-
-33
-
Price
-
$31.57
Significant Holders of CG Oncology, Inc. - Common Stock (CGON) as of Q2 2024
128 filings reported holding CGON - CG Oncology, Inc. - Common Stock as of Q2 2024.
CG Oncology, Inc. - Common Stock (CGON) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.3M shares
of 76.6M outstanding shares and own 56.52% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (5.46M shares), TCG Crossover Management, LLC (3.67M shares), BRAIDWELL LP (3.31M shares), BVF INC/IL (2.42M shares), VANGUARD GROUP INC (2.24M shares), BlackRock Inc. (1.98M shares), Yu Fan (1.58M shares), JANUS HENDERSON GROUP PLC (1.43M shares), RA CAPITAL MANAGEMENT, L.P. (1.4M shares), and RTW INVESTMENTS, LP (1.34M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.